Key result
Colchicine is associated with reduced MI and major cardiovascular outcomes across stable and unstable CAD.
Answers are grounded in this paper and cite their sources.
Coronary artery disease (CAD) is a major cause of morbidity and mortality worldwide. Inflammation has been seen to be a key feature of atherosclerosis and CAD, with a raised C-reactive protein being a marker of poor prognosis. Thus, the role of anti-inflammatory agents has been investigated in CAD. Colchicine is a well-known, inexpensive drug with marked anti-inflammatory effects. Here, we discuss the role of colchicine in stable CAD and post-acute coronary syndrome. We suggest that colchicine may play a key role in prevention of cardiovascular events in patients with stable and unstable CAD as colchicine is associated with a reduction in the rate of myocardial infarction and other major cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Katira et al. (2021) conducted a review in Coronary artery disease (stable CAD and post-acute coronary syndrome). Colchicine was evaluated on Myocardial infarction and other major cardiovascular outcomes. Colchicine is associated with a reduction in the rate of myocardial infarction and other major cardiovascular outcomes in patients with stable and unstable coronary artery disease.
Synapse has enriched 5 related papers. Consider them for comparative context: